saw that - goes back to saying what the others have said - massive demand but is RPL sufficiently better to justify a deal - doesn't seem like it yet. Always 'next year' and it seems initial approach to market as asthma drug was mis conceived - we have wasted so much time. I thought vrp was the one with the real potential. Its safety profile is the one really great attribute of rpl with lack of steroid but without partnering with another drug is its efficacy really that earth shattering? AGM attendance a great idea to ask a few pointed questions - what hurts is not so much the result - that is what it is but the total lack of detail or explanation - thought they were better then that. CEO and DoF are all we have now - if they left we really would be doomed. In till the end like you guys
Well, at least your consistent throughout the time i've been here blogging.Right or wrong you say it as it is in your opinion. :-) Hanging on and down also gl all Corbs:-)
copd news globally..
AstraZeneca, the 2nd largest British drug maker behind GSK, who bought out U.S.-based Pearl Therapeutics last year to take control of their Symbicort business (which competes with GSK's Advair), is now in the process of buying all the respiratory drugs and inhalers from the Spanish firm Almirall for up to $2.1 Billion. This will give the drug Eklira (also called Tudorza Pressair), a new inhaler for COPD ( https://www.google.com/search?q=Eklira ), whose sales are predicted to exceed $535 Million by 2018. The deal will include Almirall's entire line of respiratory products including Ebastel and their inhaler Genuair http://www.almirallsofotec.com/en/genuair_dpiIntro.html With respiratory disease on the rise, more and more pharmacutials see this as a growth area in the coming years. “Chronic respiratory disease affects hundreds of millions of people around the world,” Pascal Soriot, AstraZeneca’s chief executive, said in a statement on Wednesday. “By combining our innovative portfolios and leveraging AstraZeneca’s global scientific and commercial capabilities, we will strengthen our ability to address the entire spectrum of care in asthma and C.O.P.D.,” he added, referring to chronic obstructive pulmonary disease. The transaction, which is subject to regulatory approval, is expected to be completed by the end of 2014 http://www.bloomberg.com/news/2014-07-30/astrazeneca-to-buy-almirall-drugs-for-875-million.html http://dealbook.nytimes.com/2014/07/30/astrazeneca-to-pay-up-to-2-1-billion-for-respiratory-drugs
Same here. I have lost two thirds of my investment so have decided to hold on. I will either lose the lot or 554 will turn out to be the next big thing. If I had to bet my house on it I'm thinking I will lose the lot !! Good luck to you all
Not a bad
Idea at all AB. Let's hope that the B o D are reading these postings and realise how upset angry and as Rhodi says well and truly shafted the shareholders feel! No use selling now is my opinion and I have 2.5 mill! Wouldn't give them another penny to
We really all should attend the next AGM on mass and vent our anger and frustrations at the CEO. And ask him some very straight questions!!
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.